DK141172B - Fremgangsmåde til fremstilling af virusproteiner af influenzavirus. - Google Patents
Fremgangsmåde til fremstilling af virusproteiner af influenzavirus. Download PDFInfo
- Publication number
- DK141172B DK141172B DK85775AA DK85775A DK141172B DK 141172 B DK141172 B DK 141172B DK 85775A A DK85775A A DK 85775AA DK 85775 A DK85775 A DK 85775A DK 141172 B DK141172 B DK 141172B
- Authority
- DK
- Denmark
- Prior art keywords
- neuraminidase
- hemagglutinin
- virus
- influenza virus
- suspension
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 12
- 241000712461 unidentified influenza virus Species 0.000 title description 11
- 108010067390 Viral Proteins Proteins 0.000 title 1
- 102000005348 Neuraminidase Human genes 0.000 description 33
- 108010006232 Neuraminidase Proteins 0.000 description 33
- 101710154606 Hemagglutinin Proteins 0.000 description 27
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 27
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 27
- 101710176177 Protein A56 Proteins 0.000 description 27
- 239000000185 hemagglutinin Substances 0.000 description 27
- 241000700605 Viruses Species 0.000 description 21
- 239000000725 suspension Substances 0.000 description 13
- 108090000288 Glycoproteins Proteins 0.000 description 11
- 102000003886 Glycoproteins Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 241000187438 Streptomyces fradiae Species 0.000 description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 5
- 235000013923 monosodium glutamate Nutrition 0.000 description 5
- 229940073490 sodium glutamate Drugs 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011026 diafiltration Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- BCMWYYCCTCFRMH-UHFFFAOYSA-M sodium;4-dodecoxy-4-oxobutanoate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CCC([O-])=O BCMWYYCCTCFRMH-UHFFFAOYSA-M 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108010004032 Bromelains Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101000613243 Gadus morhua Trypsin-10 Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- -1 nicotinyl dodecyl Chemical group 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- OTNVGWMVOULBFZ-UHFFFAOYSA-N sodium;hydrochloride Chemical compound [Na].Cl OTNVGWMVOULBFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7407352 | 1974-03-05 | ||
| FR7407352A FR2262962B1 (de) | 1974-03-05 | 1974-03-05 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK85775A DK85775A (de) | 1975-11-03 |
| DK141172B true DK141172B (da) | 1980-01-28 |
| DK141172C DK141172C (de) | 1980-07-14 |
Family
ID=9135822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK85775AA DK141172B (da) | 1974-03-05 | 1975-03-04 | Fremgangsmåde til fremstilling af virusproteiner af influenzavirus. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4136168A (de) |
| JP (1) | JPS50160487A (de) |
| BE (1) | BE826275A (de) |
| CA (1) | CA1052306A (de) |
| CH (1) | CH595106A5 (de) |
| DE (1) | DE2508396A1 (de) |
| DK (1) | DK141172B (de) |
| ES (1) | ES435323A1 (de) |
| FR (1) | FR2262962B1 (de) |
| GB (1) | GB1469901A (de) |
| NL (1) | NL7502623A (de) |
| ZA (1) | ZA751357B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR68088B (de) * | 1978-02-16 | 1981-10-30 | Science Union & Cie | |
| CA1122527A (en) * | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
| US4365187A (en) * | 1980-05-15 | 1982-12-21 | Rotron Incorporated | Brushless D.C. motor |
| US4537769A (en) * | 1982-04-06 | 1985-08-27 | American Cyanamid Company | Stabilization of influenza virus vaccine |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| US7678087B2 (en) * | 1999-09-29 | 2010-03-16 | Heska Corporation | Equine intranasal delivery system |
| US6398774B1 (en) | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4029763A (en) * | 1974-08-05 | 1977-06-14 | Mount Sinai School Of Medicine Of The City University Of New York | Influenza vaccine containing purified neuraminidase antigen and method of using the same |
-
1974
- 1974-03-05 FR FR7407352A patent/FR2262962B1/fr not_active Expired
-
1975
- 1975-02-26 DE DE19752508396 patent/DE2508396A1/de not_active Withdrawn
- 1975-02-26 US US05/553,293 patent/US4136168A/en not_active Expired - Lifetime
- 1975-03-03 GB GB874375A patent/GB1469901A/en not_active Expired
- 1975-03-04 DK DK85775AA patent/DK141172B/da unknown
- 1975-03-04 JP JP50026445A patent/JPS50160487A/ja active Pending
- 1975-03-04 CA CA221,238A patent/CA1052306A/fr not_active Expired
- 1975-03-04 BE BE153990A patent/BE826275A/xx unknown
- 1975-03-05 ZA ZA00751357A patent/ZA751357B/xx unknown
- 1975-03-05 CH CH279375A patent/CH595106A5/xx not_active IP Right Cessation
- 1975-03-05 NL NL7502623A patent/NL7502623A/xx not_active Application Discontinuation
- 1975-03-05 ES ES435323A patent/ES435323A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| NL7502623A (nl) | 1975-09-09 |
| GB1469901A (en) | 1977-04-06 |
| DK141172C (de) | 1980-07-14 |
| CA1052306A (fr) | 1979-04-10 |
| US4136168A (en) | 1979-01-23 |
| ZA751357B (en) | 1976-02-25 |
| FR2262962B1 (de) | 1977-11-04 |
| CH595106A5 (de) | 1978-01-31 |
| DK85775A (de) | 1975-11-03 |
| FR2262962A1 (de) | 1975-10-03 |
| ES435323A1 (es) | 1976-12-16 |
| BE826275A (fr) | 1975-09-04 |
| AU7878175A (en) | 1976-09-09 |
| JPS50160487A (de) | 1975-12-25 |
| DE2508396A1 (de) | 1975-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101190932B1 (ko) | 인플루엔자 백신 조성물의 제조 방법 | |
| RU2496519C2 (ru) | Способ получения препарата, содержащего вирусные антигены, и применение препарата | |
| Brecher et al. | Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change | |
| Opitz et al. | Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses | |
| Kendal | A comparison of “influenza C” with prototype myxoviruses: Receptor-destroying activity (neuraminidase) and structural polypeptides | |
| EP3395826B1 (de) | Verfahren zur herstellung und verwendung von influenza virus hämagglutinin komplexen | |
| US8173021B2 (en) | Method for the preparation of sulfated cellulose membranes and sulfated cellulose membranes | |
| Buffin et al. | Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies | |
| Weigel et al. | A membrane-based purification process for cell culture-derived influenza A virus | |
| AU2005223371A1 (en) | Novel assay for the separation and quantification of hemagglutinin antigens | |
| DK141172B (da) | Fremgangsmåde til fremstilling af virusproteiner af influenzavirus. | |
| Michalski et al. | The cleavage activation and sites of glycosylation in the fusion protein of Hendra virus | |
| Bissinger et al. | Towards integrated production of an influenza A vaccine candidate with MDCK suspension cells | |
| US20220267738A1 (en) | Method For Purifying An Enveloped Virus | |
| JPH11509081A (ja) | 新規の複製プロセス | |
| Hamilton et al. | Acquisition of a novel eleven amino acid insertion directly N-terminal to a tetrabasic cleavage site confers intracellular cleavage of an H7N7 influenza virus hemagglutinin | |
| Li et al. | Protein organization in Newcastle disease virus as revealed by perturbant treatment | |
| US4195076A (en) | Process for the preparation of hemagglutinin from viral sources and methods of utilizing same | |
| Breuning et al. | A reassortant between influenza A viruses (H7N2) synthesizing an enzymatically inactive neuraminidase at 40° which is not incorporated into infectious particles | |
| Shirvan et al. | Preparation of neuraminidase-specific antiserum from the H9N2 subtype of avian influenza virus | |
| Liu et al. | Construction and comparison of different source neuraminidase candidate vaccine strains for human infection with Eurasian avian-like influenza H1N1 virus | |
| Barroso et al. | Inactivation of avian influenza viruses by hydrostatic pressure as a potential vaccine development approach | |
| Geno et al. | Rapid and efficient purification of ficolin-2 using a disposable CELLine bioreactor | |
| KR102546626B1 (ko) | 인플루엔자 바이러스 항원 정제 조건 신속 확인 시험 | |
| Scheid | Activation of parainfluenza viruses through host-dependent cleavage of an envelope glycoprotein |